Our funds
The fund

Fondita Healthcare is an actively managed, global healthcare fund. In line with the Article 9 sustainability rating, the fund’s social sustainability objective is to invest in companies that promote health and well-being, as well as access to healthcare and equality in their own business operations.

Healthcare

The fund invests in companies that address current and unmet medical needs and provide access to medicine and medical care. This is achieved by investing in companies active in innovation, production and distribution of medicines and healthcare equipment, tools and supplies as well as diagnostics and healthcare services. Operationally, the companies are to act in a socially and environmentally responsible way.

Healthcare is an incredibly interesting, structurally growing sector and one of the three megatrends that Fondita’s thematic funds invest in.

Demographic changes with an ageing population, as well as increased welfare, translate into growing demand for healthcare. Innovation and technological advances improve care and deliver new products to fulfil current and unmet demand fueling the sector’s growth.

Sustainability
Read more about the fund’s sustainability principles:

Portfolio managers

Marcus Björkstén

Portfolio Manager, Head of Portfolio Management
Fund facts

28.2.2026

Fund size (M€)
19,8
ISIN (A)
FI4000321088
ISIN (B)
FI4000321096
Currency
EUR
Management fee
2,00 % p.a.
Risk indicator
4/7
SFDR Classification
Article 9
The fund manager's comment
In February, global equity markets strengthened modestly. Key drivers included the ongoing earnings season as well as a sharp sell-off in the software sector, where companies were structurally reassessed following the launch of Anthropic’s new AI model. At the same time, geopolitical tensions between the United States and Iran escalated. Europe emerged as the clear winner...
Top holdings
Eli Lilly & Co (US)
8,6 %
AstraZeneca (SE)
6,5 %
Merck & Co (US)
5,8 %
Medtronic (US)
5,7 %
Stryker (US)
5,0 %
USA
49 %
Denmark
12 %
Sweden
12 %
Switzerland
11 %
Belgium
7 %
Return
1 month
-0,5 %
3 months
-3,3 %
6 months
4,7 %
YTD
-0,3 %
1 year
-8,1 %
3 years
8,5 %
5 years
1,0 %
since launch (14.6.2018)
45,8 %
since launch p.a.
5,0 %
Sector division
Pharma
68 %
Equipment
31 %
Cash
2 %
Top 10 holdings
Eli Lilly & Co (US)
8,6 %
AstraZeneca (SE)
6,5 %
Merck & Co (US)
5,8 %
Medtronic (US)
5,7 %
Stryker (US)
5,0 %
Jazz Pharmaceuticals (US)
4,9 %
Novartis (CH)
4,3 %
Laboratorios Farma Rovi (ES)
4,3 %
ALK-Abelló (DK)
4,0 %
Onward Medical (BE)
3,6 %
Country division
USA
49 %
Denmark
12 %
Sweden
12 %
Switzerland
11 %
Belgium
7 %
Spain
4 %
Other
5 %
Currency exposure
USD
49 %
EUR
16 %
DKK
12 %
SEK
12 %
CHF
11 %
GBP
1 %
Fees
TER
2,00 %
Subscription fee
0,00 %
Redemption fee
0,00 %

Total client relationship allow for changes in tariff rate.

Documents

FUND INFORMATION
KID
PAI Statements
Fund rules
Prospectus
REPORTS
Monthly report
Annual report
Semi-annual report
SUSTAINABILITY DOCUMENTS
ESG Report
Shared sustainability documents
Sustainability-related disclosures

This is marketing communication. The past performance of the investment fund does not provide any guarantee of future results. Read the fund prospectus and KID (Key Information Document) before making any investment decisions. The fund prospectus and KID are available on English, Finnish and Swedish at our website.

Our funds
Latest news
Fondita Sustainable World – Off to an Excellent Start in 2026

Fondita Sustainable World — a fund investing globally in climate- and environmentally smart solutions — has had a strong start to 2026, ... Read more

Fondita achieves Excellent Rating in UN PRI Assessment

UN PRI (Principles For Responsible Investments) is the most well-known independent organization focusing on responsible investments. Fondita signed the UN PRI in ... Read more

This page was last updated

Web design: Wikström Media
Fondita online Fondita
online